Actelion Ltd was the principal investor and majority shareholder of Vaxxilon AG since its inception in June 2015. In association with the Actelion acquisition by Janssen Holding GmbH, an indirect subsidiary of Johnson & Johnson, Actelion carried out a demerger of Actelion’s drug discovery and early clinical pipeline assets into Idorsia, a newly formed company, headquartered in Allschwil, Switzerland. The Vaxxilon shareholding was among these assets.

BASEL OFFICE

Vaxxilon AG
Christoph Merian-Ring 11
4153 Reinach Switzerland

BERLIN OFFICE

Vaxxilon Deutschland GmbH
Magnusstraße 11
12489 Berlin, Germany